AIM: To determine the prevalence of diabetic retinopathy and maculopathy in the Northland Diabetic Retinopathy Screening Programme. METHOD: Retrospective analysis of the latest and most severe retinopathy and maculopathy grades from each patient in the programme. RESULTS: Data from 7098 screenings from 5647 diabetics were obtained, which represented approximately 77% of the total number of diagnosed diabetics in Northland. The two main ethnic groups in our study were New Zealand European (56.5%) and Maori (39.3%). Retinopathy was present in 19% of the Northland diabetic screening population: 13.6% had minimal non-proliferative diabetic retinopathy (NPDR), 5.4% had NPDR and 0.4% had Proliferative Diabetic Retinopathy (PDR). Ethnicity data for NPDR was 57% Maori, 38% European, and PDR 50% Maori, 45% European. Maculopathy was present in 11%. Maculopathy requiring treatment was present in 1.4% (Maori 48%, European 44%). The mean failure-to-attend rate was 31%. CONCLUSION: Rates of retinopathy and maculopathy detected by the Northland screening programme were comparable to rates reported in Waikato, lower than Wellington rates and lower than international averages. Maori were over-represented in patients with retinopathy and maculopathy, but underrepresented within the screening population. The success of this programme was undermined by the high failure-to-attend rate despite attempts to improve access.
AIM: To determine the prevalence of diabetic retinopathy and maculopathy in the Northland Diabetic Retinopathy Screening Programme. METHOD: Retrospective analysis of the latest and most severe retinopathy and maculopathy grades from each patient in the programme. RESULTS: Data from 7098 screenings from 5647 diabetics were obtained, which represented approximately 77% of the total number of diagnosed diabetics in Northland. The two main ethnic groups in our study were New Zealand European (56.5%) and Maori (39.3%). Retinopathy was present in 19% of the Northland diabetic screening population: 13.6% had minimal non-proliferative diabetic retinopathy (NPDR), 5.4% had NPDR and 0.4% had Proliferative Diabetic Retinopathy (PDR). Ethnicity data for NPDR was 57% Maori, 38% European, and PDR 50% Maori, 45% European. Maculopathy was present in 11%. Maculopathy requiring treatment was present in 1.4% (Maori 48%, European 44%). The mean failure-to-attend rate was 31%. CONCLUSION: Rates of retinopathy and maculopathy detected by the Northland screening programme were comparable to rates reported in Waikato, lower than Wellington rates and lower than international averages. Maori were over-represented in patients with retinopathy and maculopathy, but underrepresented within the screening population. The success of this programme was undermined by the high failure-to-attend rate despite attempts to improve access.
Authors: Maria Valeria Jimenez-Baez; Horacio Marquez-Gonzalez; Rodolfo Barcenas-Contreras; Carlos Morales Montoya; Laura Fatima Espinosa-Garcia Journal: Colomb Med (Cali) Date: 2015-03-30
Authors: Asamere Tsegaw; Shitaye Alemu; Abere Dessie; Christopher C Patterson; Eldryd H O Parry; David I W Phillips; Elisabeth R Trimble Journal: J Ophthalmol Date: 2021-03-31 Impact factor: 1.909